Arvinas
A DMPK scientist at Arvinas contributes to drug discovery and development projects, focusing on in vitro and in vivo ADME, animal PK, toxicokinetics, drug metabolism, DDI, and human PK prediction. The role involves advising discovery teams, supporting development teams, and preparing regulatory documents.
Headquarters
New Haven, Connecticut, United States
Company Size
201-500 employees
Founded
2013
Arvinas is a biotechnology company pioneering targeted protein degradation therapeutics using its proprietary PROTAC (proteolysis-targeting chimera) platform, which designs small molecules that selectively induce degradation of disease-causing proteins rather than merely inhibiting them. The company develops therapies across oncology and neuroscience, and has achieved its first FDA-approved product, VEPPANU (vepdegestrant). Arvinas also partners with leading pharmaceutical companies and academic experts to broaden and accelerate its pipeline of protein degrader treatments.
Arvinas Stock Pre-Market (+4.7%): Broad Biotech Rally on Geopolitical De-escalation, Falling Oil
3 days ago
Arvinas Highlights Phase 1 Shift, 2026 Data Catalysts, and Vepdegestrant NDA at Barclays Conference
2 days ago
New CEO at local biotech firm is leading shift to early-stage drugs
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Arvinas.
14% below the average for this role
Arvinas (NASDAQ:ARVN) Shares Down 7.8% - What's Next?
1 day ago